skip to main content

    Updated Visitor Guidelines

 

MENU

 

Multidisciplinary Multiple Myeloma and Plasma Cell Dyscrasias Clinic

The Multidisciplinary Multiple Myeloma and Plasma Cell Dyscrasias Clinic, located at the University of Michigan Rogel Cancer Center, follows a team approach to care. Your first patient visit is with a doctor and nurse who focus exclusively on multiple myeloma care. Contact us: 734-647-8902

What is multiple myeloma?

Multiple myeloma (MM) is a type of blood cancer formed from plasma cells which are a type of white blood cell that lives in the bone marrow. MM is one of several types of plasma cell neoplasms that are diseases in which the body makes too many plasma cells.

Cancer Center surgeon receives campus diversity award

Media contact: Nicole Fawcett, 734-764-2220 | Patients may contact Cancer AnswerLine™, 800-865-1125

U-M researchers find new gene involved in blood-forming stem cells

Research has identified a gene critical to controlling the body’s ability to create blood cells and immune cells from blood-forming stem cells, a process critical during bone marrow transplant.

Researchers find protein that may signal more aggressive prostate cancers

University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.

A third of breast cancer patients concerned about genetic risk

A new study finds that many women diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer.

Panel predicts whether rare leukemia will respond to treatment

Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.

Researchers develop new potential drug for rare leukemia

Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

U-M research on lifetime risk of ovarian cancer may help women make informed decisions

The average lifetime risk of ovarian cancer is approximately 1.37 percent in non-Hispanic white women in the United States, but there are women at substantially higher and lower risk, according to the researchers, led by Celeste Leigh Pearce, associate professor of epidemiology.

Pages